Targeted Therapy
Approved for: NSCLC
Biomarker: EGFR exon 19, exon 21 L858R

Osimertinib (Tagrisso) approved Targeted Therapy for non small cell lung cancer (NSCLC) with the biomarker EGFR exon 19, exon 21 L858R.

Osimertinib (Tagrisso) is an adjuvant therapy for NSCLC patients who have undergone resection and have tumors positive for either EGFR exon 19 or exon 21 L858R.